South Africa Antibody Drug Conjugates Market Size & Outlook
South Africa antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
South Africa antibody drug conjugates market highlights
- The South Africa antibody drug conjugates market generated a revenue of USD 15.2 million in 2021 and is expected to reach USD 95.7 million by 2030.
- The South Africa market is expected to grow at a CAGR of 22.7% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 15.2 million |
| Market revenue in 2030 | USD 95.7 million |
| Growth rate | 22.7% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.3% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 95.7 million by 2030.
Blood cancer was the largest segment with a revenue share of 55.92% in 2021. Horizon Databook has segmented the South Africa antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
A large population and unmet medical needs are expected to provide major growth opportunities to ADC manufacturers. Furthermore, increase in government initiatives to provide advanced healthcare facilities and launch of new products to meet the needs of people are expected to propel market growth.
The Government of South Africa has made improvements in basic healthcare reforms by providing free primary healthcare to children and pregnant women. It has also collaborated with UN to improve healthcare measures for decreasing mortality and increasing life expectancy.
The 5-year prevalence of cancer in South Africa stands at 262,455, with breast and prostate cancers being the most common types. In addition, the prevalence of breast cancer in sub-Saharan African has increased by ~23% between 2012 and 2018, as per a study published in Frontiers in Oncology.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa antibody drug conjugates market size, by application, 2018-2030 (US$M)
South Africa Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
